Hi, what are you looking for?
By Josh Beckerman
Shares of Journey Medical were up 21%, to $2.03, as it reported favorable topline Phase 1 study data for a papulopustular rosacea treatment it is developing in collaboration with Dr. Reddy’s Laboratories.
Journey Medical said it is “very pleased” with the results for DFD-29, which indicate that it can be safely used for up…
Read the full article here
Introduction Duluth Trading (NASDAQ:DLTH) surprised a lot of investors with their results, sending the share price up nearly 20% following the release of their...
This week’s Fed meeting is extraordinary, and it could shock investors in a way we haven’t seen since 2008. So, I’m doing the weekly...
